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Background
Mutations of cysteine residues in von Willebrand factor are known to reduce the storage and
secretion of this factor, thus leading to reduced antigen levels. However, one cysteine mutation,
p.Cys2773Ser, has been found in patients with type 2A(IID) von Willebrand’s disease who have
normal plasma levels of von Willebrand factor. We hypothesize that disruption of either intra- or
interchain disulfide bonds by cysteine mutations in von Willebrand factor has different effects on
the biogenesis of Weibel-Palade bodies.
Design and Methods
The effect of specific cysteine mutations that either disrupt intrachain (p.Cys1130Phe and
p.Cys2671Tyr) or interchain (p.Cys2773Ser) disulfide bonds on storage and secretion of von
Willebrand factor was studied by transient transfection of human embryonic kidney cell line 293.
Upon expression of von Willebrand factor these cells formed endothelial Weibel-Palade body-like
organelles called pseudo-Weibel-Palade bodies. Storage of von Willebrand factor was analyzed
with both confocal immunofluorescence and electron microscopy. Regulated secretion of von
Willebrand factor was induced by phorbol 12-myristate 13-acetate. 
Results
p.Cys1130Phe and p.Cys2671Tyr reduced the storage of von Willebrand factor into pseudo-
Weibel-Palade bodies with notable retention of von Willebrand factor in the endoplasmic reticu-
lum, whereas p.Cys2773Ser-von Willebrand factor was stored normally. As expected, wild-type
von Willebrand factor formed proteinaceous tubules that were seen under electron microscopy as
longitudinal striations in pseudo-Weibel-Palade bodies. p.Cys2773Ser caused severe defects in
von Willebrand factor multimerization but the factor formed normal tubules. Furthermore, the
basal and regulated secretion of von Willebrand factor was drastically impaired by p.Cys1130Phe
and p.Cys2671Tyr, but not by p.Cys2773Ser.
Conclusions
We postulate that natural mutations of cysteines involved in the formation of interchain disulfide
bonds do not affect either the storage in Weibel-Palade bodies or secretion of von Willebrand fac-
tor, whereas mutations of cysteines forming intrachain disulfide bonds lead to reduced von
Willebrand factor storage and secretion because the von Willebrand factor is retained in the endo-
plasmic reticulum.
Key words: cysteine mutations, secretion, storage, von Willebrand factor, Weibel-Palade body,
von Willebrand’s disease.
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ABSTRACT
Introduction
Von Willebrand factor (VWF) is a multimeric plasma gly-
coprotein that facilitates platelet adhesion to an injured
vessel wall and carries coagulation factor VIII in the circu-
lation.1 Aberrations in the function or concentration of
VWF may lead to the most common human inherited
bleeding disorder von Willebrand’s disease (VWD). 
The main source of plasma VWF is the endothelial cell
which stores VWF in a unique organelle called the Weibel-
Palade body (WPB). VWF is released from WPB by basal
and regulated mechanisms.2,3 During its biosynthesis,
VWF undergoes extensive post-translational modifications
that include formation of intrachain and interchain disul-
fide bonds. The interchain disulfide bonds bridge the cys-
teine knot domains (“tail-to-tail”) and D3 domains (“head-
to-head”) of VWF to form dimers and multimers of up to
80 monomeric subunits.1,4,5 Such interchain disulfide bond
formation has recently been shown to be facilitated by the
low pH seen in the trans Golgi and WPB.6,7 Through a
process called tubulation, VWF is organized at the trans
Golgi into proteinaceous tubules that are stored in the
WPB. Under an electron microscope VWF tubules appear
as striations (if viewed longitudinally) or as hollow rings (if
viewed in cross-section).4,5
VWF contains numerous cysteines8 and a large number
of mutations of cysteines have been identified in VWD
patients with either quantitative (VWD types 1 and 3) or
qualitative (VWD type 2) defects of VWF (ISTH-SSC VWF
mutation database www.vwf.group.shef.ac.uk/). The mecha-
nisms by which specific cysteine mutations lead to the dif-
ferent clinical phenotypes of VWD are largely unknown.
Based on the expression data of cysteine mutations in
VWF, we and others have shown that intracellular reten-
tion of VWF is a common mechanism underlying VWD
with quantitative deficiencies of VWF.9-12 Recently we
showed that impaired WPB formation and reduced regu-
lated secretion of VWF contribute to this intracellular
retention.13 However, cysteines p.Cys2771 and
p.Cys2773, which are involved in interchain-disulfide
bond formation at the cysteine knot domain,14 have been
implicated in type 2A(IID) VWD in patients with normal
plasma VWF antigen level15-17 suggesting normal storage
and secretion. We, therefore, hypothesized that disruption
of interchain disulfide bonds may not hamper VWF-
induced biogenesis of WPB and secretion into the circula-
tion whereas disruption of intrachain disulfide bonds
does.
To address this hypothesis, the intracellular storage and
secretion of p.Cys2773Ser-VWF mutant was compared
with that of two other VWF mutants, p.Cys1130Phe-VWF
and p.Cys2671Tyr-VWF, in which intrachain disulfide
bonds are disrupted. We found that disruption of intra-
chain disulfide bonds in VWF by mutations p.Cys1130Phe
and p.Cys2671Tyr impairs WPB biogenesis whereas dis-
ruption of an interchain disulfide bond by p.Cys2773Ser
does not affect WPB formation. Our findings also con-
firmed that VWF tubulation and storage in WPB are not
dependent on C-terminal dimerization.
Design and Methods
Patients and mutations
The mutations investigated in this study had all been identified
earlier in VWD patients. p.Cys1130Phe (c.3389G>T) was identi-
fied in a heterozygous state in patients originally diagnosed with
type 1 VWD with moderately severe bleeding tendencies.18,19 The
phenotype of patients carrying p.Cys1130Phe has more recently
also been classified as 2A(IIE).20,21 p.Cys2671Tyr (c.8012G>A) was
described in a compound heterozygous type 3 VWD patient with
a deletion of the second allele.22 p.Cys2773Ser (c.8318G>C) was
identified in heterozygous type 2A(IID) patients.17
Plasmid constructs
Recombinant pSVH expression plasmids containing full length
cDNA encoding either the wild-type human VWF (WT-VWF) or
the p.Cys2671Tyr and p.Cys2773Ser VWF variants have been
described before.9 The full-length VWF cDNA fragments, obtained
by EcoRI restriction of these pSVH-VWF plasmids, were cloned
into the pCI-neo mammalian expression vector (Promega,
Madison, WI, USA). Mutation p.Cys1130Phe was introduced into
pCI-neo WT-VWF plasmid with the QuikChange XL Site-
Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA) and ver-
ified by sequencing.
Cell culture and transfection
Cells of the human embryonic kidney cell line 293 (HEK293)
were purchased from the American Type Culture Collection
(ATCC, Rockville, USA) and cultured in minimum essential medi-
um Eagle alpha modification (MEM-α, Sigma-Aldrich, St. Louis,
MO, USA) supplemented with 10% fetal calf serum, 2 mM L-glu-
tamine and 50 μg/mL gentamicin (Invitrogen, Carlsbad, CA, USA).
Using the FuGENE HD transfection reagent (Roche Diagnostics,
Mannheim, Germany), 0.66 μg/mL plasmid constructs (final con-
centration in the medium; 0.33 μg/mL WT-VWF and mutant VWF
plasmids for co-transfections) were transiently transfected into
HEK293 cells according to the manufacturer’s instruction. 
Immunofluorescent staining and antibodies
Transfected cells were stained with immunofluorescent anti-
bodies and analyzed with a Leica SL confocal laser scanning
microscope with a 63X/1.40 NA oil objective, as previously
described.13 Monoclonal antibody CLB-RAg35 and polyclonal rab-
bit anti-human protein disulfide isomerase (PDI) antibody A66
(obtained from Prof. I. Braakman, Department of Chemistry,
Utrecht University, Utrecht, The Netherlands) were used as pri-
mary antibodies against VWF and the endoplasmic reticulum (ER)
marker PDI, respectively.23,24 Alexa 488- and Alexa 594-conjugated
secondary antibodies were purchased from Invitrogen. To quanti-
fy the extent of retention of VWF in the ER, we determined the
percentage of cells expressing VWF which also showed retention
of VWF in the ER by co-staining the VWF with PDI.
Transmission electron microscopy
Transfected cells grown on 35-mm Petri dishes were fixed and
prepared for transmission electron microscopy as previously
described.13,25 Briefly, cells treated with osmium tetroxide and tan-
nic acid were serially dehydrated with ethanol and embedded in
Epon. The samples cut into thin sections of 70-100 nm were
stained with uranyl acetate and lead citrate, and then analyzed
with a Tecnai 12 at 120 kV equipped with a 4kx4k CCD camera
(Model Eagle, Fei Company, The Netherlands).
Structural analysis of von Willebrand factor 
Seventy-two hours after transfection cells were incubated with
release medium [OPTIMEM1 medium, 10 mM HEPES (N-2-
hydroxyethylpiperazine-N’-2-ethanesulfonic acid), 0.2% bovine
serum albumin, pH 7.4] for 24 h. The conditioned media were
electrophoresed through 1.6% agarose gel containing 1% sodium
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dodecyl sulfate for multimer analysis. VWF multimers were visu-
alized by western blotting as described elsewhere.9
Electrophoresis and blotting were performed under non-reducing
conditions. To analyze the processing of VWF, reducing sodium
dodecyl sulfate polyacrylamide gel electrophoresis and western
blotting were performed for the conditioned media and cell
lysates. Cell lysates were prepared with Passive Lysis Buffer
(Promega) supplemented with 100 μM phenylmethylsulfonyl flu-
oride (Roche) and the protease inhibitor cocktail CompleteTM with
EDTA (Roche). Samples were reduced using 20 mM dithiothreitol,
separated by Novex 6% Tris-Glycine gel electrophoresis
(Invitrogen), immunostained with polyclonal rabbit anti-human
VWF conjugated to horseradish peroxidase (DAKO) and visual-
ized with Supersignal WestFemto (Thermo Scientific, Rockford,
IL, USA).
Basal and regulated secretion of von Willebrand factor
In the absence of stimulation, VWF is mainly secreted via the
basal secretory pathway from WPB.3 HEK293 cells are known to
form pseudo-WPB that are similar to the WBP in endothelial
cells.13 Basal and regulated secretion of VWF was determined as
previously described.13 Briefly, 24 h after transfection, cells were
incubated with fresh culture medium for 48 h and then the condi-
tioned media and cell lysates were collected to determine basal
secretion of VWF. To analyze the regulated secretion of VWF, 72 h
after transfection cells were incubated for 60 min with release
medium containing 160 nM phorbol 12-myristate 13-acetate
(PMA) (Sigma-Aldrich) or vehicle (dimethylsulfoxide). VWF:Ag in
the media and cell lysates was determined by an enzyme-linked
immunosorbent assay. For the calculation of regulated secretion,
secreted VWF was expressed as a fraction of total VWF (amount in
the medium plus lysate). Statistical analyses were performed with
Student’s t-test using GraphPad Prism software (version 4.02).
Results
Retention of von Willebrand factor in the endoplasmic
reticulum
As shown in Figure 1, WT-VWF formed numerous elon-
gated pseudo-WPB organelles. Each of the VWF mutants
was able to form pseudo-WPB although these organelles
were relatively short or more granular compared with
those formed by WT-VWF. As indicated by the co-local-
ization of VWF and the ER marker PDI, both
p.Cys1130Phe and p.Cys2671Tyr led to considerable
retention of synthesized VWF in the ER. In contrast, most
of the p.Cys2773Ser-VWF was stored in pseudo-WPB
similar to those observed for WT-VWF. Quantification of
VWF storage showed that 60-80% of cells expressing
p.Cys1130Phe or p.Cys2671Tyr displayed retention of
VWF in the ER, whereas this was less than 10% for WT-
VWF or p.Cys2773Ser-VWF (Figure 1). The retention of
p.Cys1130Phe-VWF in the ER was reduced by co-trans-
fection with WT-VWF. In this case the proportion of cells
showing ER retention of VWF decreased from 83% to
26%. There was no reduction in ER retention of
p.Cys2671Tyr-VWF upon co-transfection with WT-VWF.
The different efficiencies in storage of VWF variants were
also reflected by PMA-induced pseudo-WPB exocytosis
(see section on Secretion of VWF).
Analysis of the cell ultrastructure with transmission
electron microscopy revealed pseudo-WPB containing
VWF tubules in cells expressing WT-VWF as well as each
of the mutants (Figure 2A-E). The tubules formed by the
three VWF mutants appeared normal compared to those
formed by WT-VWF (Figure 2A).25 This indicates that all
Biogenesis of Weibel-Palade bodies in VWD variants
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Figure 1. Intracellular localization
of VWF variants in transfected
HEK293 cells. HEK293 cells were
transiently transfected with WT-
VWF or VWF mutants as indicated.
Fixed cells were stained for VWF
(left panel, green) and for PDI (the
ER marker, middle panel, red). In
the right panel (merge of green
and red channels), the pseudo-
WPB show up in green (VWF stain-
ing only), and the ER containing
VWF shows up in yellow as a result
of double staining for VWF and PDI.
Scale bar = 5 μm. Between 175
and 370 cells expressing each of
the VWF variants from two inde-
pendent experiments were ana-
lyzed and the percentage of cells
that showed retention of VWF in
the ER (cells displaying yellow) is
indicated on the right.






three mutants were able to form pseudo-WPB although
p.Cys1130Phe-VWF did so rarely. Furthermore, grossly
dilated ER was frequently observed in cells expressing
p.Cys1130Phe (Figure 2F) or p.Cys2671Tyr (Figure 2G).
The ER morphology in cells expressing p.Cys2773Ser was
normal (Figure 2H).
The retention of VWF mutants in the ER was further
confirmed, using western blotting under reducing condi-
tions, by evaluating the extent to which VWF was
processed into its mature form. Secreted VWF consisted
mainly of fully processed mature VWF subunits (Figure
3A). In the cell lysates, both mature subunits and
uncleaved pro-VWF were detectable for all VWF variants
(Figure 3B). However, p.Cys1130Phe-VWF and
p.Cys2671Tyr-VWF showed relatively much more
uncleaved pro-VWF compared to WT-VWF and
p.Cys2773Ser-VWF (Figure 3C), indicating that
p.Cys1130Phe-VWF and p.Cys2671Tyr-VWF were
retained in the ER, and did not reach the Golgi apparatus
where furin cleaves pro-VWF.26-28
Secretion of von Willebrand factor
WPB contributes to both the basal and regulated secre-
tion of VWF.3 To determine the effect of pseudo-WPB for-
mation on the secretion of VWF mutants, both secretory
pathways were examined. Basal secretion of VWF was
defined as the secreted VWF:Ag level in the conditioned
medium over 48 h (Online Supplementary Table S1).
Compared to WT-VWF, both p.Cys1130Phe-VWF and
p.Cys2671Tyr-VWF showed significantly reduced basal
secretion, which was apparent from a decrease in VWF
level in the medium as well as from the decreased ratio of
VWF:Ag in medium over lysate. In contrast, the basal
secretion of the p.Cys2773Ser variant of VWF was nor-
mal, with a similar medium/lysate ratio as that of WT-
VWF.
To mimic the heterozygous state of the mutations in
carriers, cells were co-transfected with VWF mutants and
WT-VWF at a 1:1 ratio. After this co-transfection with
WT-VWF and mutant VWF, the basal secretion of
VWF:Ag into medium was similar for all three mutants.
However, the decreased ratio of VWF:Ag in medium over
lysate observed for p.Cys1130Phe-VWF and
p.Cys2671Tyr-VWF indicates that the secretion of these
VWF variants remained compromised in the heterozy-
gous state (Online Supplementary Table S1). Furthermore,
the absolute amount of VWF protein produced by WT-
VWF or the three variants was similar (total VWF:Ag in
the medium and lysates; about 100 mU VWF per 7×105
cells) for both single transfections and co-transfections,
J.w. wang et al.
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Figure 2. Ultrastructure of transfected HEK293 cells visualized by transmission electron microscopy. HEK293 cells were transiently transfected as
indicated. Pseudo-WPB displaying VWF tubules were formed by WT-VWF (A) and the three mutants (B-E). Dilated ER was observed in cells express-
ing p.Cys1130Phe (F) or p.Cys2671Tyr (G) but not in cells expressing p.Cys2773Ser (H) or WT-VWF (not shown). Note that the VWF tubules were
clearly visualized in the cross sections of pseudo-WPB (indicated by the arrows in panels B and E). The ER (indicated by the arrowheads) shown
in panels F, G and H was imaged in the same cells shown in panels B, C and D, respectively. The stars in panels C, G and H indicate mitochondria.
In panel A-E, scale bar = 200 nm; in panels F-H, scale bar = 500 nm.
confirming that the effects on WPB formation and ER
retention of VWF (Figure 1) could not be explained by the
expression level of the mutants. The secretion and total
amount (medium plus lysate) of p.Cys2773Ser-VWF was
higher than that of WT-VWF, although the difference was
not statistically significant (Online Supplementary Table S1;
126.5 mU in single transfections and 117.7 mU in co-
transfections versus 97.9 mU for WT-VWF per 7×105 cells),
consistent with the normal to high plasma levels of VWF
in the patients.17 Rapid clearance in vivo was shown to
account for the more severe phenotypes of patients with
p.Cys1130Phe-VWF and p.Cys2671Tyr-VWF.29
The regulated secretion of VWF was analyzed by using
PMA, which efficiently induces exocytosis of pseudo-
WPB in HEK293 cells.13 Incubation of HEK293 cells for 60
min with PMA increased the secretion of WT-VWF by
2.7-fold (12.2% of total VWF was secreted by PMA-stim-
ulated cells versus 4.5% by control cells, Figure 4). Both
p.Cys1130Phe- and p.Cys2773Ser-transfected cells
showed good response to PMA stimulation although the
total secretion of p.Cys1130Phe-VWF was much lower.
Only a minimal increase in the secretion of
p.Cys2671Tyr-VWF was observed after stimulation. Co-
transfections with p.Cys2773Ser or p.Cys1130Phe pro-
duced a regulated secretion of VWF comparable to that of
WT-VWF if judged by the fold increases, but to a much
lower absolute level in the case of p.Cys1130Phe. Co-
transfection of p.Cys2671Tyr only slightly increased the
secretion of VWF during stimulation. These in vitro data
for p.Cys1130Phe (co-transfection mimicking the het-
erozygous state) and p.Cys2671Tyr (single transfection
mimicking the compound heterozygous state) are consis-
tent with the response to DDAVP infusion in the patients
with these mutations.29,30 One may speculate that patients
with p.Cys2773Ser will show a normal response to
DDAVP; however, no patient was available for direct test-
ing.
Multimeric analysis of secreted von Willebrand factor
We performed multimer analysis of the conditioned
media (Figure 5). A full range of VWF multimers was pres-
ent in the conditioned medium for WT-VWF and
p.Cys2671Tyr-VWF, while p.Cys1130Phe-VWF showed
relative loss of large multimers indicating that mutations
close to the interchain disulfide bonds may have a minor
but significant effect on VWF multimerization.
p.Cys2773Ser-VWF mainly formed monomers and
dimers. The appearance of double bands for the dimers
was caused by the different mobility between C-terminal
dimers and N-terminal dimers formed by p.Cys2773Ser.17
The multimeric defects caused by p.Cys1130Phe and
p.Cys2773Ser were only partly restored by co-transfec-
tion with WT-VWF. This is consistent with the multimer
patterns in the patients.17,19,20 Furthermore, the odd-num-
bered VWF multimers produced by co-transfection of
p.Cys2773Ser with WT-VWF confirmed co-expression of
both constructs in individual cells.
Discussion
Chemical modification and mutagenesis studies have
demonstrated that cysteines p.Cys2771 and p.Cys2773
are involved in interchain disulfide bond formation and
are equally essential for VWF dimerization.14 Natural
mutations in the two cysteines lead to essentially the same
Biogenesis of Weibel-Palade bodies in VWD variants
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Figure 3. Subunit composition of VWF under
reducing conditions. HEK293 cells were tran-
siently transfected with WT-VWF or VWF
mutants as indicated. VWF secreted into the
medium (A: Medium) or VWF retained in
lysate (B: Lysate) was reduced with DTT and
analyzed with SDS-PAGE and western blot-
ting. In panel C, the ratio of proVWF (p) and
mature VWF subunit (m) in the cell lysate
was analyzed with Image J (NIH software,
version 1.44P). Note that in panels A and B
the parts separated by the space between
p.Cys2671Tyr and p.Cys2773Ser are from
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clinical phenotype.15-17 In addition, extensive studies have
indicated that p.Cys1130 at the N-terminal and p.Cys2671
at the C-terminal are not involved in the interchain disul-
fide bonds but rather are involved in the intrachain disul-
fide bonds.14,31,32 We, therefore, selected the three muta-
tions p.Cys2773Ser, p.Cys1130Phe and p.Cys2671Tyr that
were identified in our center17,18,22 as exemplary mutants to
examine the differential effects of interchain versus intra-
chain disulfide bonds on WPB biogenesis. p.Cys2773Ser-
VWF was normally stored in and secreted from transfect-
ed HEK293 cells despite strongly reduced dimerization
and multimerization. In contrast, p.Cys1130Phe and
p.Cys2671Tyr resulted in strong retention of VWF in the
ER and less VWF stored in pseudo-WPB, which is consis-
tent with previous reports for other cysteine mutations
that disrupt intrachain disulfide bonds in VWF.13,33 Our
data, therefore, suggest that VWF mutations that disrupt
interchain disulfide bonds differ from mutations that dis-
rupt intrachain disulfide bonds in the effect on WPB bio-
genesis.
The mutations that were analyzed in this study are
located in different domains in VWF: p.Cys1130Phe in
the D3 domain, p.Cys2671Tyr in the region immediately
amino-terminal to the cysteine knot domain and
p.Cys2773Ser in the cysteine knot domain itself. The dif-
ferent phenotypes of these mutations may be ascribed to
the fact that they disrupt different domains of VWF but
the differences in phenotypes may also be related to inter-
chain versus intrachain defects. Several cysteine muta-
tions, all involved in intrachain disulfide bonds, located in
the D’ (p.Cys788Arg), D3 (p.Cys1060Tyr, p.Cys1149Arg
and p.Cys1225Gly) and cysteine knot (p.Cys2739Tyr and
p.Cys2754Trp) domains showed very similar disruptive
effects on the storage and secretion of VWF as
p.Cys1130Phe and p.Cys2671Tyr.13,33 This suggests that
the effects are not domain-specific. Furthermore,
p.Cys2739Tyr and p.Cys2754Trp in the cysteine knot
domain are not stored properly, whereas p.Cys2773Ser in
the same domain but involved in interchain disulfide
bonds showed normal storage.13 In addition, another
mutation p.Cys1099Tyr in the D3 domain that disrupts
interchain disulfide bonds between N-termini of VWF
was identified in VWD type II C Miami patients charac-
terized by normal plasma level of VWF.31,34,35 Even stronger
support for our hypothesis comes from the 2010 version of
the ISTH-SSC VWF mutation database (www.vwf.group.
shef.ac.uk/). It lists with 72 different mutations involving
cysteine residues, 50 with loss of cysteines, 18 with gain of
cysteines and 4 with premature stop codons (Online
Supplementary Table S2). Among these mutations, 42 that
predict the loss of intrachain disulfide cysteines are associ-
ated with low plasma levels of VWF, whereas five
(p.Cys1099Tyr, p.Cys2771Ser/Tyr and p.Cys2773Arg/Ser)
that predict the loss of interchain disulfide cysteines are
associated with normal to relatively high plasma levels of
VWF.14-17,31,35 We, therefore, believe that the differences are
related to differential effects of mutations involved in intra-
chain versus interchain disulfide bonds.
We propose a model to explain the differential effects of
intrachain versus interchain disulfide bonds on WPB for-
mation (Figure 6). Disruption of intrachain disulfide bonds
in VWF may mainly disturb the conformation of VWF
such that the ER quality control system prevents traffick-
ing to the Golgi apparatus.36 The retained VWF molecules
either aggregate in the ER to lead to ER dilation (Figure 2F-
G)13,33 or undergo intracellular degradation.13,37 Some
mutant VWF molecules appear to escape the quality con-
trol system and are able to reach the Golgi apparatus. The
extent to which this escape takes place appears to depend
J.w. wang et al.
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Figure 4. Regulated secretion of WT-VWF or VWF variants. HEK293
cells were transiently transfected with WT-VWF, p.Cys1130Phe,
p.Cys2671Tyr and p.Cys2773Ser, respectively (Panel A). In panel B,
p.Cys1130Phe, p.Cys2671Tyr or p.Cys2773Ser was co-transfected
with WT-VWF at a 1:1 ratio. Seventy-two hours after transfection
HEK293 cells were rinsed twice with the release medium and incu-
bated at 37°C for 60 min in the release medium without (Ctr) or
with 160 nM PMA (PMA). Each bar represents VWF secreted into the
release medium as a fraction of total VWF (medium plus lysate)
times 100%. The mean and SEM are based on three independent
experiments in duplicate. The numbers above the bars indicate the
fold increase of secreted VWF comparing the stimulated (PMA) and
control (Ctr) samples.
Figure 5. Multimer analysis of secreted VWF. Multimers are shown for
single transfections (A) and co-transfections with WT-VWF at a 1:1
ratio (B). The N-terminal dimers and odd-numbered multimers formed
by VWF p.Cys2773Ser are indicated by the arrow and arrowheads,
respectively. In panel A, the multimers of VWF p.Cys2671Tyr are from
a different gel, the other separated parts are from the same gel. In
panel B, the separated parts are from the same gel. The multimer pat-
terns of secreted VWF were analyzed by SDS-agarose gel electrophore-


























































































































on the nature of the defects. Once the mutants get to the
trans Golgi, where further processes of VWF are highly
regulated by pH,6,7,38 their effects are minimal unless the
defects cause severe changes in VWF conformation. In
contrast, disruption of interchain disulfide bonds such as
that in the VWF C-termini does not hamper trafficking to
the Golgi apparatus and WPB thereafter. C-terminal
dimerization of VWF is not, therefore, required for WPB
formation. According to the notion that N-terminal dimer-
ization (i.e. multimerization) of VWF is not required for
WPB formation,39 the mutations that disrupt interchain
disulfides in VWF N-terminal may not disrupt the biogen-
esis of WPB as well. It is thus tempting to speculate that
unpairing all the five interchain disulfide bonds (two at the
N-terminal and three at the C-terminal) should have min-
imal, if any, effect on the storage and secretion of VWF.
Tubulation is a key step in the storage of VWF into
WPB. Recent studies provide emerging evidence in sup-
port of a hypothesis that VWF tubulation is regulated by
the low pH in transGolgi and WPB.7,38,40,41 In a cell-free sys-
tem with low pH as in trans Golgi, Huang and colleagues
showed that truncated N-terminal dimers of VWF D’D3
domains together with VWF propeptide formed tubular
structures by self-assembly.38 The present data confirmed
this finding for full-length VWF in a cell system. The VWF
p.Cys2773Ser that forms N-terminal dimers17 and partly
remains as monomers showed normal tubulation (Figure
2E). The persistence of monomers raises two questions: (i)
whether (and how) the monomers are stored into pseudo-
WPB; and (ii) are these monomers able to form VWF
tubules? As VWF is mainly secreted from WPB via basal
and regulated pathways, the large amount of monomers
that was detected in the medium of cells expressing
p.Cys2773Ser (Figure 5A) suggests that VWF monomers
are probably stored in the pseudo-WPB. Furthermore,
immunofluorescent staining showed that very little VWF
p.Cys2773Ser was localized in the ER (Figure 1D), indicat-
ing that the excessive monomers found in the lysate (data
not shown) are indeed stored in the pseudo-WPB. It is
unknown whether those monomers are able to form
tubules in the transGolgi network as it has been suggested
that N-terminal dimerization is required for the tubulation
of VWF in a cell-free system.38 Strikingly, Zhou and col-
leagues observed a dimeric bouquet-like VWF complex
formed at the acidic pH of the trans Golgi and WPB.7 The
C-terminal dimer of VWF was zipped up by the acidic pH
from the cysteine knot to B1 domain (six domains) into a
dimeric stem. This process was proposed to facilitate
VWF tubulation.7 As such, unpairing the interchain disul-
fide bonds at the cysteine knot domain, for example, by
mutation p.Cys2773Ser, would unlock the start point of
the zip. It is unknown whether the stability and/or con-
formation of the dimeric complex would be affected. As
formation of the dimeric complex is highly pH-depen-
dent, the p.Cys2773Ser monomers are likely to form the
bouquet-like complex and, therefore, to incorporate into
VWF tubules. In contrast, VWF mutations p.Cys2739Tyr
and p.Cys2754Trp which cause severe conformational
changes by defects in intrachain disulfide bonds led to dis-
organized tubular storage of VWF.13 This suggests that the
conformational changes in VWF may be more disruptive
to VWF tubulation than no interchain pairing.
In conclusion, we postulate that natural mutations of
cysteines involved in the formation of interchain disulfide
bonds, p.Cys2771, p.Cys2773 and p.Cys2811 in the cys-
teine knot domain and p.Cys1099 and p.Cys1142 in the
D3 domain, do not affect the storage and secretion of
VWF, whereas mutations of cysteines forming intrachain
disulfide bonds lead to reduced VWF storage and secretion
due to ER retention.
Authorship and Disclosures
The information provided by the authors about contributions from
persons listed as authors and in acknowledgments is available with
the full text of this paper at www.haematologica.org.
Financial and other disclosures provided by the authors using the
ICMJE (www.icmje.org) Uniform Format for Disclosure of
Competing Interests are also available at www.haematologica.org.
Biogenesis of Weibel-Palade bodies in VWD variants
haematologica | 2012; 97(6) 865
Figure 6. Schematic illustration of VWF
intracellular trafficking. WT-VWF (left)
is synthesized and dimerized in the ER,
and passes the quality control in the
Golgi apparatus to multimerize and
tubulize therein, and is eventually
packed into WPB. Some of the VWF
mutants with impaired intrachain disul-
fide bond formation (middle) escape
the quality control and are stored in
WPB, the others are retained in the ER
undergoing aggregation or intracellular
degradation. VWF mutants with
impaired C-terminal interchain disul-
fide bond formation (right) fail to form
C-terminal dimers in the ER. The
monomers can get through the ER to
the Golgi and partly form N-terminal
dimers which are tubulized and stored
into WPB. The remaining monomers
are presumably stored into WPB; how-
ever, whether they are incorporated
into VWF tubules is unknown. This
hypothesis may also apply to the
mutants lacking N-terminal interchain
disulfide bonds. TGN: trans Golgi net-
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